Erythropoietin impairs endothelial vasodilatory function in patients with renal anemia and in healthy subjects

Nephron - Clinical Practice

Volumn 102, Issue 1, 2006, Pages

  Annuk, Margus ^a,b   Linde, Torbjörn ^a   Lind, Lars ^a   Fellström, Bengt ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b TALLINN UNIVERSITY   (Estonia)

Author keywords

Chronic renal failure; Endothelium; Epoetin alfa

Indexed keywords

HEMOGLOBIN; METHACHOLINE; NITROPRUSSIDE SODIUM; RECOMBINANT ERYTHROPOIETIN; SODIUM CHLORIDE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD FLOWMETRY; BLOOD PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INFUSION; ENDOTHELIAL DYSFUNCTION; FEMALE; FOREARM BLOOD FLOW; HUMAN; INFUSION; KIDNEY ANEMIA; MALE; PATIENT; PRIORITY JOURNAL; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASODILATATION; VEIN OCCLUSION PLETHYSMOGRAPHY;

ADULT; ANEMIA; BLOOD PRESSURE; ENDOTHELIUM, VASCULAR; EPOETIN ALFA; ERYTHROPOIETIN; FEMALE; FOREARM; HEMATINICS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; REGIONAL BLOOD FLOW; VASODILATION;

EID: 32844456192     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088308     Document Type: Article

References (20)

1. Singbartl G: Adverse events of erythropoietin in long-term and in acute/short-term treatment. Clin Invest 1994;72:s36-s43.
2. London GM, Zins B, Pannier B, Naret C, Berthelot JM, Jacquot C, Safar M, Drueke TB: Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. Kidney Int 1989;36:878-882.
3. Harrison DG, Cai H: Endothelial control of vasomotion and nitric oxide production (review). Cardiol Clin 2003;21:289-302.
4. Vogel V, Kramer HJ, Backer A, Meyer-Lehnert H, Jelkmann W, Fandrey J: Effects of erythropoietin on endothelin-1 synthesis and the cellular calcium messenger system in vascular endothelial cells. Am J Hypertens 1997;10:289-296.
5. Bode-Böger SM, Böger RH, Kuhn M, Radermacher J, Frölich JC: Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int 1996;50:1255-1261.
6. Wang XQ, Vaziri ND: Erythropoietin depresses nitric oxide synthase expression by human endothelial cells. Hypertension 1999;33:894-899.
7. Taddei S, Virdis A, Mattei P, Salvetti A: Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993;21:929-933.
8. Schachinger V, Britten MB, Zeiher AM: Prognostic impact of coronary vasodilatory function on the long-term outcome of coronary heart disease. Circulation 2000;101:1899-1906.
9. Benjamin N, Calver A, Collier J, Robinson B, Vallance P, Webb D: Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension 1995;25:918-923.
10. Lind L, Hall J, Larsson A, Annuk M, Fellström B, Lithell H: Evaluation of endothelium-dependent vasodilation in the human peripheral circulation. Clin Physiol 2000;20:440-448.
11. Lind L, Sarabi M, Millgård J: Methodological aspects of the evaluation of endothelium-dependent vasodilation in the human forearm. Clin Physiol 1998;18:81-87.
12. Egrie JC, Lane J, Gaines Das RE, Tam RC: Development of radioimmunoassay for human erythropoietin using recombinant erythropoietin as a tracer and immunogen. J Immunol Methods 1987;99:235-241.
13. Wada Y, Matsuoka H, Tamai O, Kohno K, Okuda S, Imaizumi T: Erythropoietin impairs endothelium-dependent vasorelaxation through cyclooxygenase-dependent mechanisms in humans. Am J Hypertens 1999;12:980-987.
14. Noguchi K, Yamashiro S, Matsuzaki T, Sakanashi M, Nakasone J, Miyagi K, Sakanashi M: Effect of 1-week treatment with erythropoietin on the vascular endothelial function in anaesthetized rabbits. Br J Pharmacol 2001;133:395-405.
15. Kusano E, Akimoto T, Umino T, Yanagiba S, Inoue M, Ito C, Ando Y, Asano Y: Modulation of endothelin-1-induced cytosolic free calcium mobilization and mitogen-activated protein kinase activation by erythropoietin in vascular smooth muscle cells. Kidney Blood Press Res 2001;24:192-200.
16. Berglund B, Ekblom B: Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy men. J Intern Med 1991;229:125-130.
17. Vaziri ND: Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis 1999;33:821-828.
18. Banerjee D, Rodriguez M, Nag M, Adamson JW: Exposure of endothelial cells to recombinant human erythropoietin induces nitric oxide synthase activity. Kidney Int 2000;57:1895-1904.
19. Blum M, Yachnin T, Wollman Y, Chernihovsky T, Peer G, Grosskopf I, Kaplan E, Silverberg D, Cabili S, Iaina A: Low nitric oxide production in patients with chronic renal failure. Nephron 1998;79:265-268.
20. Linde T, Sandhagen B, Danielson BG, Wikström B: Impaired erythrocyte fluidity during treatment of renal anemia with erythropoietin. J Intern Med 1998;231:601-606.